APOB and metabolic syndrome: Emerging evidence suggests that integrating waist circumference (WC) with biochemical markers—particularly plasma triglycerides (TG) and apolipoprotein B (ApoB)—may enhance risk stratification accuracy by quantifying both abdominal adiposity topography and VAT‐associated dyslipidemia [4].